Arcus Biosciences Rises 15%

Shares of oncology-focused biopharmaceutical company Arcus Biosciences, Inc. (RCUS) are trading 15 percent higher on Thursday. The company on Wednesday reported positive clinical activity from its three-arm randomized Phase 2 ARC-7 study.

The company said that the first interim analysis of the three-arm randomized Phase 2 ARC-7 study, with both arms being domvanalimab-based combinations showed encouraging clinical activity when given as a first-line treatment to people with metastatic, non-small cell lung cancer. Arcus Biosciences said that all the trials will continue as planned and data will presented at year-end.

The stock is currently trading at $27.00, up $3.65 or 15% on the NYSE. RCUS has traded between $16.69 and $42.36 during the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.
Follow RTT